Abstract
BackgroundImmune checkpoint inhibitors (ICIs) are now a first-line treatment option for patients with pleural mesothelioma with the recent approval of ipilimumab and nivolumab. Mesothelioma has a low tumor mutation burden...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have